348 related articles for article (PubMed ID: 17525906)
21. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
[TBL] [Abstract][Full Text] [Related]
22. Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia.
Lee SM; Lee WS; Shin HJ; Lee JJ; Sohn SK; Moon JH; Eom HS; Won JH; Lee KH; Lee JH; Kim DY; Yoon SS; Kim I; Jung CW; Kim SJ; Kim H; Lee JH; Ryoo HM; Lee GW; Kim SH; Mun YC; Kim MK; Joo YD;
Ann Hematol; 2013 Aug; 92(8):1101-10. PubMed ID: 23558905
[TBL] [Abstract][Full Text] [Related]
23. Intact T-cell regenerative capacity in childhood acute lymphoblastic leukemia after remission induction therapy.
Moritz B; Eder J; Meister B; Heitger A
Med Pediatr Oncol; 2001 Feb; 36(2):283-9. PubMed ID: 11452936
[TBL] [Abstract][Full Text] [Related]
24. [Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group].
Janka-Schaub GE; Stührk H; Kortüm B; Graubner U; Jürgens H; Spaar HJ; Schöck V; Dohrn B; Bahr R; Winkler K
Klin Padiatr; 1991; 203(4):231-5. PubMed ID: 1942930
[TBL] [Abstract][Full Text] [Related]
25. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].
Magrath I; Shanta V; Advani S; Adde M; Arya LS; Banavali S; Bhargava M; Bhatia K; Gutiérrez M; Liewehr D; Pai S; Sagar TG; Venzon D; Raina V
Eur J Cancer; 2005 Jul; 41(11):1570-83. PubMed ID: 16026693
[TBL] [Abstract][Full Text] [Related]
26. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
[TBL] [Abstract][Full Text] [Related]
27. Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG.
van der Werff Ten Bosch J; Suciu S; Thyss A; Bertrand Y; Norton L; Mazingue F; Uyttebroeck A; Lutz P; Robert A; Boutard P; Ferster A; Plouvier E; Maes P; Munzer M; Plantaz D; Dresse MF; Philippet P; Sirvent N; Waterkeyn C; Vilmer E; Philippe N; Otten J
Leukemia; 2005 May; 19(5):721-6. PubMed ID: 15744348
[TBL] [Abstract][Full Text] [Related]
28. A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion.
Kitchen BJ; Balis FM; Poplack DG; O'Brien M; Craig CE; Adamson PC
Clin Cancer Res; 1997 May; 3(5):713-7. PubMed ID: 9815740
[TBL] [Abstract][Full Text] [Related]
29. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.
Bajel A; George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
Pediatr Blood Cancer; 2008 Nov; 51(5):621-5. PubMed ID: 18688848
[TBL] [Abstract][Full Text] [Related]
30. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
[TBL] [Abstract][Full Text] [Related]
31. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors.
Cairo MS; Siegel S; Anas N; Sender L
Cancer Res; 1989 Feb; 49(4):1063-6. PubMed ID: 2536292
[TBL] [Abstract][Full Text] [Related]
32. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97.
Escherich G; Horstmann MA; Zimmermann M; Janka-Schaub GE;
Leukemia; 2010 Feb; 24(2):298-308. PubMed ID: 20016530
[TBL] [Abstract][Full Text] [Related]
33. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
Spiegler BJ; Kennedy K; Maze R; Greenberg ML; Weitzman S; Hitzler JK; Nathan PC
J Clin Oncol; 2006 Aug; 24(24):3858-64. PubMed ID: 16921038
[TBL] [Abstract][Full Text] [Related]
34. Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09.
Schramm F; Zimmermann M; Jorch N; Pekrun A; Borkhardt A; Imschweiler T; Christiansen H; Faber J; Feuchtinger T; Schmid I; Beron G; Horstmann MA; Escherich G
Leuk Lymphoma; 2019 Jan; 60(1):60-68. PubMed ID: 29966458
[TBL] [Abstract][Full Text] [Related]
35. Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: a pediatric oncology group study.
Graham ML; Shuster JJ; Kamen BA; Land VJ; Borowitz MJ; Camitta B; Cheo DL; Harrison MP; Leventhal BG; Pinkel DP; Pullen DJ; Steuber P; Whitehead VM
Clin Cancer Res; 1996 Feb; 2(2):331-7. PubMed ID: 9816176
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter.
Lauten M; Stanulla M; Zimmermann M; Welte K; Riehm H; Schrappe M
Klin Padiatr; 2001; 213(4):169-74. PubMed ID: 11528550
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients.
Rodman JH; Sunderland M; Kavanagh RL; Ochs J; Yalowich J; Evans WE; Rivera GK
Cancer Res; 1990 Jul; 50(14):4267-71. PubMed ID: 2194652
[TBL] [Abstract][Full Text] [Related]
38. Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
Hiddemann W; Schleyer E; Unterhalt M; Zühlsdorf M; Rolf C; Reuter C; Kewer U; Uhrmeister C; Wörmann B; Büchner T
Leukemia; 1992 Dec; 6(12):1273-80. PubMed ID: 1453772
[TBL] [Abstract][Full Text] [Related]
39. [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].
Muszyńska-Rosłan K; Konstantynowicz J; Krawczuk-Rybak M
Pol Merkur Lekarski; 2007 Oct; 23(136):271-5. PubMed ID: 18293849
[TBL] [Abstract][Full Text] [Related]
40. [Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Pediatric Leukemia/Lymphoma Study Group experience].
Derwich K; Wachowiaki J; Kaczmarek-Kanoldi M; Balcerska A; Balwierz W; Chybicka A; Kowalczyk JR; Matysiak M; Jackowska T; Sońta-Jakimczyk D; Wysocki M; Chełmecka-Hanuszewicz L; Cwiklińska M; Kołtan A; Malinowska I; Odój T; Płoszyńska A; Steczowicz M; Wojciechowska V; Wójtowicz A;
Przegl Lek; 2006; 63(1):7-10. PubMed ID: 16892891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]